SAStephen Akuma Aricha

Stephen Akuma Aricha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stephen Akuma Aricha has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Coverage and Factors associated with utilization of Pyrethroid-Piperonyl Butoxide treated nets in Malaria Endemic Region, Western Kenya

    by Stephen Akuma Aricha, Maurice Owiny, Fredrick Odhiambo, Judith Mangeni, Elvis Oyugi

    Background: Increased resistance to pyrethroid based Long-Lasting Insecticidal Nets (LLINs) informed WHO recommendation to deploy Piperonyl Butoxide (PBO) based LLINs. Kenya adopted use of PBO nets in endemic areas, though coverage is not known. We determined coverage and factors associated with utilization of PBO nets in a malaria endemic county. Methods: A cross-sectional study was conducted with multi-stage sampling in Matayos Sub-County, Busia County. Data were collected using questionnaire from June-July 2022. Data was analyzed by Stata version 16. Universal coverage was defined as ownership of one PBO net for two household members. Proper utilization was defined as sleeping under a mosquito net the previous night, net usage on all days of the week, hanging the net adequately. Data was collected on net ownership, access, utilization. Proper utilization of nets was the dependent variable. We calculated measures of central tendency and dispersion for continuous variables and proportions for categorical variables. Odds ratio with 95% confidence intervals was used to test for association between dependent and independent variables and variables with a p-value< 0.05 were considered to be statistically significant. Results A total of 402 participants were interviewed; mean age was 41.2 years (±16.7 years), 268 (66.7%) resided in rural areas, 77.9% (313) were female, 71.4% (287) were married, 45% (181) had at least 8 years of formal education and 86.6% (348) had informal occupations. Among all respondents, 86.3% (347) had bed nets, 92.8% (322/347) were PBO nets. A total of 64.9% (261) households attained universal coverage for bed nets. The utilization of PBO treated LLINs was significantly lower in households with heads in informal occupations compared to those in formal occupations (aOR = 0.29, 95% CI = 0.11-0.78). Additionally, households without universal coverage for bed nets had significantly lower odds of utilizing a PBO-treated LLIN compared to those with universal coverage (aOR = 0.01, 95% CI = 0.01-0.03). Conclusion: Universal coverage of PBO nets was below the national target (80%). Occupation and universal coverage were associated with the utilization of PBO nets. We recommend for continuous PBO nets distribution through additional innovative channels.

  • Open Access

    Comparison of GeneXpert and line probe assay for detection of Mycobacterium tuberculosis and rifampicin-mono resistance at the National Tuberculosis Reference Laboratory, Kenya

    by S. A. Aricha, L. Kingwara, N. W. Mwirigi, L. Chaba, T. Kiptai, J. Wahogo, J. S. Otwabe, P. O. Onyango, M. Karanja, C. Ayieko, et al.

    Background: The dual challenge of low diagnostic sensitivity of microscopy test and technical challenge of performing a TB culture test poses a problem for case detection and initiation of Tuberculosis (TB) second-line treatment. There is thus need for a rapid, reliable and easily accessible assay. This comparative analysis was performed to assess diagnostic performance characteristics of GeneXpert MTB/RIF and Line Probe Assay (LPA). Methods: Three hundred twenty nine sputum samples of patients across the 47 counties in Kenya suspected to have drug resistant TB were picked and subjected to GeneXpert, LPA and Culture MGIT at the National TB Reference Laboratory. Sensitivity, specificity and predictive values were then determined to assess the performance characteristics of the various assays. Results: Against culture MGIT as the gold standard for TB diagnosis, GeneXpert had a sensitivity, specificity, positive predictive value, and negative predictive value of 78.5, 64.9, 59.4 and 82.2% respectively while LPA had 98.4, 66.0, 65.4 and 98.4%. For diagnosis of rifampicin mono-resistance GeneXpert had a moderate agreement (Kappa 0.59, P < 0.01) (sensitivity 62.50%, specificity 96.50%) while LPA that had almost perfect agreement (Kappa = 0.89, p < 0.01) with a (sensitivity 90.0% and specificity 99.1%). Conclusion: LPA has a better performance characteristic to GeneXpert and an alternative to culture with regards to detection of RIF’s mono-resistance.